Each system was tested on 100 capillary blood samples from different subjects (≥18 years, diabetes type 1 or type 2 or no diabetes) following procedures described in ISO 15197:2003. Comparison measurements were performed on capillary plasma with a glucose oxidase laboratory method (YSI 2300 STAT Plus™ glucose analyser, YSI Incorporated, Yellow Springs, OH, USA). To confirm trueness and preci sion of the comparison method, regular internal and external quality control measures were performed.
Letter to the Editor
The standard ISO (International Organization for Standard ization) 15197 1 is widely accepted for the accuracy assess ment of systems for selfmonitoring of blood glucose (SMBG). In the European Union, manufacturers have to pro vide evidence of conformity with ISO 15197 to obtain the Conformité Européene (CE) mark for their meter. However, application of the CE mark is a 1time procedure before the market approval; regular and independent accuracy evalua tions of marketreleased test strip lots of a SMBG system are not mandatory. In fact, studies have repeatedly shown that individual test strip lots of available systems do not comply with ISO 15197 accuracy criteria. 25 In this study, 3 CEmarked SMBG systems (CareSens N, CareSens N POP, alphacheck professional) with 3 different test strip lots each were procured by the manufacturer (iSENS, Inc, Korea) to assess compliance to accuracy crite ria stipulated in ISO 15197:2003. In addition, more stringent criteria of its revision, ISO 15197:2013, 6 were applied.
The study was performed at the Institut für Diabetes Technologie Forschungs und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany in compliance with the German Medical Devices Act. The study protocol was approved by the Ethics Committee and the Federal Institute for Drugs and Medical Devices.
Each system was tested on 100 capillary blood samples from different subjects (≥18 years, diabetes type 1 or type 2 or no diabetes) following procedures described in ISO 15197:2003. Comparison measurements were performed on capillary plasma with a glucose oxidase laboratory method (YSI 2300 STAT Plus™ glucose analyser, YSI Incorporated, Yellow Springs, OH, USA). To confirm trueness and preci sion of the comparison method, regular internal and external quality control measures were performed.
Each of the tested systems fulfilled with all 3 tested lots accuracy criteria of ISO 15197:2003 with 99.5% to 100% of measurement results within ±15 mg/dl of the comparison measurement at glucose concentrations <75 mg/dl and within ±20% at glucose concentrations ≥75 mg/dl (Table 1) . Applying the tighter criteria of the revision ISO 15197:2013, the systems showed 98% to 100% of measurement results within ±15 mg/dl of the comparison measurement at glucose concentrations <100 mg/dl and within ±15% at glucose con centrations ≥100 mg/dl. Consensus error grid analysis as required by ISO 15197:2013 showed for each system 100% of measurement results within zones A and B. The relative bias according to Bland and Altman, that is, average across all differences between SMBG results and comparison method measurement results divided by their mean, ranged from 1.3% to 2.3% for CareSens N, from −0.7% to 1.6% for CareSens N POP and from −0.3% to 0.9% for alphacheck professional.
All 3 systems fulfilled with all 3 investigated test strip lots accuracy requirements of the international standard ISO 15197:2003 and its revision ISO 15197:2013, for which mandatory compliance is recommended after a 36month transition period. In bias analysis for all 3 systems minimal lottolot variability was observed. Regular and independent evaluations after the market approval of a SMBG system is helpful to ensure constant measurement quality and adher ence of marketreleased test strips to accuracy requirements stipulated in ISO 15197. The consensus error grid counts only individual BG results with comparison measurement results <550 mg/dl and BG system measurement results <550 mg/dl. Results that did not fall within these limits were not assessed.
